Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

33.93USD
2 Dec 2016
Change (% chg)

$0.38 (+1.13%)
Prev Close
$33.55
Open
$33.87
Day's High
$34.00
Day's Low
$33.67
Volume
3,790,173
Avg. Vol
4,001,720
52-wk High
$59.00
52-wk Low
$30.89

Select another date:

Tue, Nov 29 2016

Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

UPDATE 1-Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile in patients with type 2 diabetes, results released by the company on Tuesday showed.

UPDATE 1-TDC loses major contract with Novo Nordisk to Telenor

COPENHAGEN, Nov 29 Danish telecoms group TDC has lost a major contract in Denmark after one of the country's biggest employers, Novo Nordisk, said it chose Norway's Telenor as its telecoms supplier.

TDC loses major contract with Novo Nordisk to Telenor

COPENHAGEN, Nov 29 Danish telecoms group TDC has lost a major contract in Denmark after one of the country's biggest employers, Novo Nordisk, said it chose Norway's Telenor as its telecoms supplier.

Novo, Sanofi go head to head as FDA clears new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

UPDATE 2-Novo, Sanofi go head to head as FDA clears new diabetes drugs

* Companies to sell two-drug products at discount (Adds detail on pricing, quote from Novo Nordisk executive)

BRIEF-Novo Nordisk to offer discount on Xultophy in U.S.

* Says it will begin negotiations with buyers of its combination diabetes drug Xultophy in the United States by offering a 20 percent discount to the combined price of Tresiba and Victoza.

How drug price pressure helped sink Novo's insulin pill

LONDON Commercial rather than technical hurdles ultimately torpedoed Novo Nordisk's bid to make an oral form of insulin, its chief executive said on Wednesday, underscoring the impact of U.S. price pressure on the world's top insulin supplier.

How drug price pressure helped sink Novo's insulin pill

LONDON, Nov 16 Commercial rather than technical hurdles ultimately torpedoed Novo Nordisk's bid to make an oral form of insulin, its chief executive said on Wednesday, underscoring the impact of U.S. price pressure on the world's top insulin supplier.

Select another date: